Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of CPV-104 in healthy participants and patients with C3 glomerulopathy
NL-OMON59708Phase 1Recruiting
- Sponsor
- Greenovation Biotech GmbH
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of CPV-104 in Complement 3 glomerulopathy (C3G) (2 arms), sponsored by Greenovation Biotech GmbH. Primary endpoint: Primary endpoint(s). Started Dec 2025; status: recruiting.
02
Drugs
CPV-104
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NL-OMON59708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59708.